Venous and arterial thrombosis in patients receiving immune checkpoint inhibitors
Patients receiving ICPi have elevated risks of venous thrombosis and arterial thrombosis. Occurrence of venous thrombosis or arterial thrombosis during treatment with ICPi is associated with an increased mortality risk.
Authors
- Britt B.M. Suelmann (ORCID: https://orcid.org/0000-0002-7155-3337)
- Saskia Haitjema (ORCID: https://orcid.org/0000-0001-5465-4868)
- Karin A. H. Kaasjager (ORCID: https://orcid.org/0000-0001-6958-8285)
- A LENT
- Marianne Christina Verhaar (ORCID: https://orcid.org/0000-0002-3276-6428)
- Gürbey Ocak (ORCID: https://orcid.org/0000-0003-4288-7685)
- Meriem Khairoun (ORCID: https://orcid.org/0000-0003-4833-9639)
- Rebeca Puscasu
Institutions
- University Medical Center Utrecht (NL)
- St. Antonius Ziekenhuis (NL)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1371/journal.pone.0321112
- Citations
- 5
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.23